Clinical Trial Update: Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC [Phase 2]

View source ↗

Summary

Phase II study evaluating tislelizumab combined with cetuximab and irinotecan for recurrent, refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN